Cancel
Sonoma BioTherapeutics
See Linkedin
Sonoma BioTherapeutics Employees
5 people indexed:
-
q8j2kw1@wfzf52827.t05 Sign up to see email
-
xy092yht2@7hjv7e7u7.zjx Sign up to see email
-
k54x4e@l7w6zyquy.l7q Sign up to see email
-
ve.77ktd@qxhh4f8wd.kxu Sign up to see email
-
pt.3x71gh@068hjftky.tp2 Sign up to see email
Sonoma BioTherapeutics Company Information
Sonoma BioTherapeutics, based in South San Francisco and Seattle, is a clinical-stage biotechnology company dedicated to advancing engineered regulatory T cell (Treg) therapies. The company was founded by leaders in Treg biology and cell therapy. It employs proprietary platform technologies to develop targeted and durable Treg cell therapies aimed at treating autoimmune and inflammatory diseases. Sonoma BioTherapeutics has initiated Phase 1 studies for its Treg therapy and Teff biologic. The company’s leading candidates include SBT-77-7101, a novel Treg-based therapy for rheumatoid arthritis and hidradenitis suppurativa, and SBT-11-5301, an effector T Cell-modulating biologic designed for autoimmune diseases. In collaboration with Regeneron, Sonoma BioTherapeutics is working to discover, develop, and commercialize innovative Treg therapies. Additionally, the company is enhancing its production capabilities by building its own manufacturing facility in Seattle and has developed a proprietary manufacturing process that ensures robust yields of engineered Treg cells.
Report inaccurate information
Report inaccurate information
